Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study
Journal of Bone and Mineral Metabolism · 2024
DOI: 10.1007/s00774-023-01477-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Bone and Mineral Metabolism, 2024. Verfasst von Akimitsu Miyauchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Miyauchi Medical Center, Osaka, Japan. Hauptthemen laut MEDLINE: Osteoporosis, Fractures, Bone, Bone Density Conservation Agents, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Amgen, Astellas Pharma, UCB Pharma.
Abstract (Originalsprache)
INTRODUCTION: To describe the real-world use of romosozumab in Japan, we conducted a chart review of > 1000 Japanese patients with osteoporosis (OP) at high risk of fracture, across multiple medical institutions. MATERIALS AND METHODS: Treatment-naïve and prior OP-treatment patients who received romosozumab for 12 months followed by ≥ 6 months of sequential OP treatment were included. The primary objective described the baseline demographics and clinical characteristics; secondary objectives evaluated changes in bone mineral density (BMD) and bone turnover markers in all patients and effectiveness of romosozumab in a sub-group of treatment-naïve patients using the fracture risk assessment tool (FRAX®). RESULTS: Of the 1027 patients (92.4% female), 45.0% were treatment-naïve. The mean ± SD age of treatment-naïve versus prior OP-treatment patients was 76.8 ± 8.5 and 77.1 ± 8.5 years. The most frequent prior OP treatment was bisphosphonates (45.0%). Romosozumab treatment for 12 months increased BMD at the lumbar spine in all groups; the median percent change from baseline in lumbar spine BMD was higher in the treatment-naïve (13.4%) versus prior OP-treatment group (bisphosphonates [9.2%], teriparatide [11.3%], denosumab [DMAb, 4.5%]). DMAb, bisphosphonates, or teriparatide after romosozumab maintained the BMD gains at all skeletal sites at month 18 in treatment-naïve patients. Most treatment-naïve patients were at high risk of fracture, BMD increased consistently with romosozumab regardless of the baseline fracture risk assessed by FRAX. CONCLUSION: This large-scale, multicenter chart review provides clinically relevant insights into the profiles of patients initiating romosozumab, effectiveness of real-world romosozumab use, and sequential therapy in Japanese patients at high risk of fracture.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Miyauchi Medical Center, Osaka, Japan.
- Amgen K.K., Midtown Tower 9-7-1 Akasaka, Minato-ku, Tokyo, 107-6239, Japan. ehamaya@amgen.com.
- Amgen K.K., Midtown Tower 9-7-1 Akasaka, Minato-ku, Tokyo, 107-6239, Japan.
Förderung
- Amgen
- Astellas Pharma
- UCB Pharma
Zitieren
APA
Miyauchi, A., Hamaya, E., Shimauchi, J., Yoshinaga, Y., & Nishi, K. (2024). Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study. Journal of Bone and Mineral Metabolism. https://doi.org/10.1007/s00774-023-01477-0
Vancouver
Miyauchi A, Hamaya E, Shimauchi J, Yoshinaga Y, Nishi K. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study. Journal of Bone and Mineral Metabolism. 2024. doi:10.1007/s00774-023-01477-0
BibTeX
@article{Miyauchi2024,
author = {Miyauchi, Akimitsu and Hamaya, Etsuro and Shimauchi, Junichiro and Yoshinaga, Yoko and Nishi, Kiyoshi},
title = {Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study},
journal = {Journal of Bone and Mineral Metabolism},
year = {2024},
doi = {10.1007/s00774-023-01477-0}
}
EUVIMED